Imprimis Pharmaceuticals (IMMY +12%) ramps higher today after the company says that had concluded its Type C meeting with the FDA, which included the review of the development plan for its lead phase 3 drug candidate, Impracor, a topical cream Non-Steroidal Anti-Inflammatory Drug.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs